Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Publication | Closed Access

DOI

713

Citations

References

2016

Year

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, Hans‐Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst,

The Lancet Oncology

Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineSurgical PathologyGastroenterologyPathologySurgeryGastrointestinal PathologyCancer TreatmentPhase 2OncologyHistopathological RegressionCancer ResearchRandomised Phase 2/3